Nephros Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nephros Inc 's ROA in the third quarter of 2026?
Nephros Inc achieved a return on average assets (ROA) of 13.06 % in its third quarter of 2026, this is above NEPH's average return on assets of -62.27%.
Nephros Inc assets over the 12 months ending in its third quarter of 2026 are valued at $15 million

Despite the company's net income deteriorating, Nephros Inc was able to improve its ROA compared to the second quarter of 2026.

However, within the Healthcare sector 77 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2026 from 756 to 1057.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	15.54 %	28.81 %	17.12 %	21.69 %	27.55 %
Y / Y Net Income Change	51.93 %	405.06 %	-74.91 %	-82.23 %	84.15 %
Net Income (TTM) in million	2	2	1	1	1
Return On Assets (TTM)	13.06 %	12.3 %	5.86 %	9.38 %	12.22 %
NEPH's Total Ranking	# 1057	# 756	# 482	# 493	# 879
Total Assets (TTM) in million	15	16	14	14	13
Seq. Total Assets Change	-2.95 %	14.33 %	1.12 %	2.97 %	8.2 %
Seq. Net Income Change	-57.23 %	755 %	125.81 %	-81.6 %	42.19 %

NEPH's 5 Years Annual ROA >> Back to NEPH Management Effectiveness >> Compare NEPH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 19
Sector	# 78
Overall	# 475

Return On Assets Statistics
High	Average	Low
35.32 %	-62.27 %	-248.08 %
(Dec 31 2013)		(Dec 31 2014)

Financial Statements
Nephros Inc 's Assets	$ 15 million	NEPH's Balance sheet
Nephros Inc 's Income	$ 1 million	Quarterly NEPH's Income Statement
NEPH's Income by Division		See NEPH's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	21.69 %	-5.49 %	7.84 %	-37.68 %	-69.25 %
Total Assets in million	14	11	12	11	18
Y / Y Net Income Change	1513.51 %	-	-	-	-
Net Income in million	1	0	-2	-7	-4
Annual Return On Assets	8.75 %	0.66 %	-13.28 %	-64.61 %	-23.27 %

NEPH's 5 Years Annual ROA >> Back to NEPH Management Effectiveness >> Compare NEPH ROA to its Competitors

Comment on NEPH's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 8.75 % compared to prior year, due to annual net income growth of 1513.51 % to $1.19 million, while value of Nephros Inc 's overall assets grew just by 21.69 % to $13.64 million, compared to $13.64 a year before.

More Return On Assets Ratios
NEPH's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NEPH's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NEPH's Competitors
Subscribers only: Roa for Nephros Inc 's Suppliers
Subscribers only: Return On Assets for NEPH's Customers

You may also want to know
NEPH's Roi	NEPH's Inventory Turnover Ratio	NEPH's Growth Rates	NEPH's Dividend Comparisons
	NEPH's Profitability Ratios	NEPH's Asset Turnover Ratio	NEPH's Dividend Growth
NEPH's Roe	NEPH's Valuation Ratios	NEPH's Financial Strength Ratios	NEPH's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %
Lantheus Holdings Inc	11.43 %

Date modified: 2026-11-06T12:56:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.